---
figid: PMC7353012__cancers-12-01424-g003
figtitle: Functions of UCA1, lincRNA-ROR, and lncRNA MIR2052HG in the tamoxifen resistance
  of breast cancer
organisms:
- Homo sapiens
- Mus musculus
- Glycine max
- Mouse mammary tumor virus
organisms_ner:
- Homo sapiens
- Mus musculus
- Danio rerio
pmcid: PMC7353012
filename: cancers-12-01424-g003.jpg
figlink: pmc/articles/PMC7353012/figure/cancers-12-01424-f003/
number: F3
caption: 'Schematic representation of the functions of UCA1, lincRNA-ROR, and lncRNA
  MIR2052HG in the tamoxifen resistance of breast cancer. (A) UCA1 promotes the tamoxifen
  resistance by several mechanisms. UCA1 activates mTOR, Wnt/β-catenin, and PI3K/AKT
  signaling pathways to enhance tamoxifen resistance. In addition, UCA1 binds to EZH2
  and epigenetically suppresses p21 expression. Moreover, UCA1 sponges miR-18 to upregulate
  HIF1α expression. Since HIF1α induces UCA1 expression, UCA1 and HIF1α form a feedback
  regulatory loop to strengthen tamoxifen resistance. (B) LincRNA-ROR enhances tamoxifen
  resistance by inhibiting autophagy. Moreover, lincRNA-ROR induces the degradation
  of an ERK-specific phosphatase, DUSP7, resulting in ERα activation mediated by the
  MAPK/ERK signaling pathway. LincRNA-ROR also acts as a competing endogenous RNA
  (ceRNA), which sponges miR-205-5p to upregulate the expression of EMT-related genes
  ZEB1/2 and contributes to tamoxifen resistance. (C) MIR2052HG increases the expression
  of LMTK3. LMTK3 suppresses the activity of PKC, which increases the expression of
  ESR1 mRNA and ERα protein through the inactivation of AKT and MEK/ERK/RSK1 signaling
  pathway, respectively. UCA1: urothelial cancer associated 1; lincRNA-ROR: large
  intergenic noncoding RNA-regulator of reprogramming; MIR2052HG: miR2052 host gene;
  mTOR: mammalian target of rapamycin; PI3K: phosphoinositide 3-kinase; EZH2: enhancer
  of zeste homolog 2; HIF1α: hypoxia-inducible factor 1α; DUSP7: dual specificity
  phosphatase 7; MAPK/ERK: mitogen-activated protein kinase (MAPK)/extracellular signal-regulated
  kinase (ERK); ZEB1/2: zinc finger E-box binding homeobox 1/2; LMTK3: lemur tyrosine
  kinase 3; PKC: protein kinase C; ESR1: estrogen receptor 1; MEK: MAPK/ERK kinase;
  RSK1: ribosomal S6 kinase 1.'
papertitle: Long Noncoding RNAs Involved in the Endocrine Therapy Resistance of Breast
  Cancer.
reftext: Toshihiko Takeiwa, et al. Cancers (Basel). 2020 Jun;12(6):1424.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9460741
figid_alias: PMC7353012__F3
figtype: Figure
redirect_from: /figures/PMC7353012__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7353012__cancers-12-01424-g003.html
  '@type': Dataset
  description: 'Schematic representation of the functions of UCA1, lincRNA-ROR, and
    lncRNA MIR2052HG in the tamoxifen resistance of breast cancer. (A) UCA1 promotes
    the tamoxifen resistance by several mechanisms. UCA1 activates mTOR, Wnt/β-catenin,
    and PI3K/AKT signaling pathways to enhance tamoxifen resistance. In addition,
    UCA1 binds to EZH2 and epigenetically suppresses p21 expression. Moreover, UCA1
    sponges miR-18 to upregulate HIF1α expression. Since HIF1α induces UCA1 expression,
    UCA1 and HIF1α form a feedback regulatory loop to strengthen tamoxifen resistance.
    (B) LincRNA-ROR enhances tamoxifen resistance by inhibiting autophagy. Moreover,
    lincRNA-ROR induces the degradation of an ERK-specific phosphatase, DUSP7, resulting
    in ERα activation mediated by the MAPK/ERK signaling pathway. LincRNA-ROR also
    acts as a competing endogenous RNA (ceRNA), which sponges miR-205-5p to upregulate
    the expression of EMT-related genes ZEB1/2 and contributes to tamoxifen resistance.
    (C) MIR2052HG increases the expression of LMTK3. LMTK3 suppresses the activity
    of PKC, which increases the expression of ESR1 mRNA and ERα protein through the
    inactivation of AKT and MEK/ERK/RSK1 signaling pathway, respectively. UCA1: urothelial
    cancer associated 1; lincRNA-ROR: large intergenic noncoding RNA-regulator of
    reprogramming; MIR2052HG: miR2052 host gene; mTOR: mammalian target of rapamycin;
    PI3K: phosphoinositide 3-kinase; EZH2: enhancer of zeste homolog 2; HIF1α: hypoxia-inducible
    factor 1α; DUSP7: dual specificity phosphatase 7; MAPK/ERK: mitogen-activated
    protein kinase (MAPK)/extracellular signal-regulated kinase (ERK); ZEB1/2: zinc
    finger E-box binding homeobox 1/2; LMTK3: lemur tyrosine kinase 3; PKC: protein
    kinase C; ESR1: estrogen receptor 1; MEK: MAPK/ERK kinase; RSK1: ribosomal S6
    kinase 1.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - UCA1
  - MIR2052HG
  - EZH2
  - MTOR
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - CTNNB1
  - AKT1
  - AKT2
  - AKT3
  - LMTK3
  - MIR18A
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - LINC-ROR
  - EPHB2
  - MAPK1
  - MAPK3
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - RPS6KA1
  - ESR1
  - DUSP7
  - ERAL1
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - ZEB1
  - Ezh2
  - Mtor
  - Ctnnb1
  - Akt1
  - Lmtk3
  - Mir18
  - Cdkn1a
  - Nsg1
  - Tpt1
  - Tceal1
  - pc
  - pk
  - Ephb2
  - Mapk1
  - Rps6ka1
  - Esr1
  - Dusp7
  - Eral1
  - Zeb1
  - ezh2
  - mtor
  - ctnnb1
  - lmtk3
  - mir18a
  - cdkn1a
  - esr1
  - akap12b
  - dusp7
  - zeb1b
---
